[PERSON]
Konstantinos Xynos
Featured in 2 tracked stories · first seen
Situations
Replimune Tudriqev FDA approval and subsequent legal action
5 clusters · 20 sources · last updated
Latest: Replimune faces lawsuits following TUDRIQEV approval
On 6 August 2026, the FDA granted accelerated approval to Replimune’s oncolytic herpes-virus therapy RP1, marketed as Tudriqev, for use with Bristol Myers Squibb’s Opdivo (nivolumab) in adults with unresectable or metast
Replimune Group financial and insider activity
2 clusters · 3 sources · last updated
Latest: Replimune Group shares rise amid CFO stock sale
Replimune Group has experienced recent financial and leadership activity. In mid-August, CEO Sushil Patel, CFO Emily Luisa Hill, and insider Konstantinos Xynos sold shares to cover tax withholding obligations related to